#22 – Tom Dayspring Part III of V: reverse cholesterol transport, CETP inhibitors, & apolipoproteins

ℹ️ EPISODE INFO

Released

January 1, 2020

Duration

1h 4m

Channel

Peter Attia MD

Watch on YouTube

▶ Open ↗

📝 EPISODE DESCRIPTION

Sign up to receive Peter's email newsletter: https://bit.ly/4c602k2 Original release date: 10/17/18 In this five-part series, Thomas Dayspring, M.D., FACP, FNLA, a world-renowned expert in lipidology, and one of Peter’s most important clinical mentors, shares his wealth of knowledge on the subject of lipids. In Part III, Peter and Tom dig into why “reverse cholesterol transport” is a lot more nuanced than what most of us are taught, lipid transport, apolipoproteins, and more. In addition, this episode highlights the complexity of HDL and a discussion about the CETP inhibitor trials. We discuss: -Reverse cholesterol transport [1:40]; -Lipid transportation, apolipoproteins, VLDL, IDL, and LDL particles [11:00]; -Remnant lipoproteins and apoC-III [16:45]; -Particles having sex: lipid exchange [28:00]; -Cholesteryl Ester Transfer Protein (CETP) and CETP inhibitors [40:45]; -2006 CETP inhibitor trial: torcetrapib (Pfizer) [54:45]; -2012 CETP inhibitor trial: dalcetrapib (Hoffmann–La Roche) [56:15]; -2017 CETP inhibitor trials: evacetrapib (Eli Lilly) and anacetrapib (Merck) [58:00]; and -More. Show notes page: https://peterattiamd.com/tomdayspring3/ About: The Peter Attia Drive is a weekly, ultra-deep-dive podcast focusing on maximizing health, longevity, critical thinking…and a few other things. With over 10 million episodes downloaded, it features topics including fasting, ketosis, Alzheimer’s disease, cancer, mental health, and much more. Peter is the founder of Attia Medical, PC, a medical practice with offices in San Diego and New York City, focusing on the applied science of longevity. The practice applies nutritional biochemistry, exercise physiology, sleep physiology, techniques to increase distress tolerance, lipidology, pharmacology, and four-system endocrinology to increase lifespan (delaying the onset of chronic disease), while simultaneously improving healthspan (quality of life). Learn more: https://peterattiamd.com/ Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe/ Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/ Connect with Peter on: Facebook: http://bit.ly/PeterAttiaMDFB Twitter: http://bit.ly/PeterAttiaMDTW Instagram: http://bit.ly/PeterAttiaMDIG Subscribe to The Drive: Apple Podcast: http://bit.ly/TheDriveApplePodcasts Overcast: http://bit.ly/TheDriveOvercast Spotify: http://bit.ly/TheDriveSpotify Google Play: http://bit.ly/TheDriveGooglePlay

🎤 SPEAKERS

• Peter Attia

  host

  Physician and host of The Peter Attia Drive, focused on longevity and metabolic health.

• Tom Dayspring

  guest

  Lipidologist and expert on lipoproteins, atherosclerosis, and cardiovascular risk biomarkers.

🧾 EPISODE SUMMARY

In this episode of Peter Attia MD, featuring Peter Attia and Tom Dayspring, #22 – Tom Dayspring Part III of V: reverse cholesterol transport, CETP inhibitors, & apolipoproteins explores rethinking HDL, Reverse Cholesterol Transport, and Why CETP Inhibitors Failed Dayspring argues the old picture of HDL simply carrying cholesterol back to the liver is far too simple, since cholesterol also moves via the intestine, red blood cells, albumin and LDL particles.

🔗 RELATED EPISODES

409 ‒ Inside modern drug development: the science, economics, and regulatory hurdles

#117 – Stanley Perlman, M.D., Ph.D.: Insights from a coronavirus expert on COVID-19

#150-Senator Bill Frist, MD: A modern Renaissance man's journey through science, politics & business

#130 - Carol Tavris, Ph.D. & Elliot Aronson, Ph.D.: Recognizing and overcoming cognitive dissonance

#96–David Epstein: How range of experience leads to better performance in a highly specialized world

#125 - John Arnold: The most prolific philanthropist you may not have heard of